FDA Approves FOUNDAYO Orforglipron Type 1 New Molecular Entity

FDA granted approval for FOUNDAYO (orforglipron calcium), marking the first approval of this new molecular entity. The drug is approved in six dosage strengths ranging from 0.8mg to 17.2mg base equivalents, administered as an oral tablet under prescription status. Eli Lilly and Company is the approved NDA holder, with the 17.2mg strength designated as the Reference Listed Drug (RS) for potential generic competition.

Pharmaceutical manufacturers and healthcare providers should note that orforglipron represents a new chemical entity in the GLP-1 receptor agonist class, creating potential compliance considerations around prescribing, dispensing, and adverse event reporting. Generic manufacturers may reference the 17.2mg RS strength when filing Abbreviated New Drug Applications (ANDAs). The Prescription-only marketing status means no over-the-counter dispensing is permitted.